CR20130565A - FUSIONATES DERIVED FROM USEFUL IMIDAZOL AS IDO INHIBITORS - Google Patents

FUSIONATES DERIVED FROM USEFUL IMIDAZOL AS IDO INHIBITORS

Info

Publication number
CR20130565A
CR20130565A CR20130565A CR20130565A CR20130565A CR 20130565 A CR20130565 A CR 20130565A CR 20130565 A CR20130565 A CR 20130565A CR 20130565 A CR20130565 A CR 20130565A CR 20130565 A CR20130565 A CR 20130565A
Authority
CR
Costa Rica
Prior art keywords
fusionates
imidazol
derived
useful
ido inhibitors
Prior art date
Application number
CR20130565A
Other languages
Spanish (es)
Inventor
Mario Mautino
Sanjeev Kumar
Jesse Waldo
Firoz Jaipuri
Tanay Kesharwani
Xiaoxia Zhang
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Priority to CR20130565A priority Critical patent/CR20130565A/en
Publication of CR20130565A publication Critical patent/CR20130565A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El triptófano (Trp) es un aminoácido esencial necesario para la biosíntesis de proteínas, niacina y del neurotransmisor 5 hidroxitriptamina (serotonina). La enzima indoleamina 2,3 dioxigenasa (también conocida como INDO o IDO) cataliza el primer paso que limita la tasa de degradación de L triptófano en N formil quinureninaTryptophan (Trp) is an essential amino acid necessary for the biosynthesis of proteins, niacin and the neurotransmitter 5 hydroxytryptamine (serotonin). The enzyme indoleamine 2,3 dioxygenase (also known as INDO or IDO) catalyzes the first step that limits the degradation rate of L tryptophan in N formyl quinurenine

CR20130565A 2013-11-04 2013-11-04 FUSIONATES DERIVED FROM USEFUL IMIDAZOL AS IDO INHIBITORS CR20130565A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CR20130565A CR20130565A (en) 2013-11-04 2013-11-04 FUSIONATES DERIVED FROM USEFUL IMIDAZOL AS IDO INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CR20130565A CR20130565A (en) 2013-11-04 2013-11-04 FUSIONATES DERIVED FROM USEFUL IMIDAZOL AS IDO INHIBITORS

Publications (1)

Publication Number Publication Date
CR20130565A true CR20130565A (en) 2014-05-26

Family

ID=50884156

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130565A CR20130565A (en) 2013-11-04 2013-11-04 FUSIONATES DERIVED FROM USEFUL IMIDAZOL AS IDO INHIBITORS

Country Status (1)

Country Link
CR (1) CR20130565A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075341A1 (en) * 2015-10-29 2017-05-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as ido/tdo inhibitors
CN107176956A (en) * 2017-05-31 2017-09-19 成都海博锐药业有限公司 A kind of IDO inhibitor compound, Pharmaceutical composition, purposes
WO2017198159A1 (en) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 Imidazole derivative containing bridge ring
CN107488179A (en) * 2016-06-11 2017-12-19 鲁南制药集团股份有限公司 Imidazoles 01 derivatives containing bridged ring
WO2018045966A1 (en) * 2016-09-12 2018-03-15 广州必贝特医药技术有限公司 Imidazole-containing fused tricyclic compounds and applications thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075341A1 (en) * 2015-10-29 2017-05-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as ido/tdo inhibitors
US10308647B2 (en) 2015-10-29 2019-06-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as IDO/TDO inhibitors
WO2017198159A1 (en) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 Imidazole derivative containing bridge ring
CN107488179A (en) * 2016-06-11 2017-12-19 鲁南制药集团股份有限公司 Imidazoles 01 derivatives containing bridged ring
WO2018045966A1 (en) * 2016-09-12 2018-03-15 广州必贝特医药技术有限公司 Imidazole-containing fused tricyclic compounds and applications thereof
CN107176956A (en) * 2017-05-31 2017-09-19 成都海博锐药业有限公司 A kind of IDO inhibitor compound, Pharmaceutical composition, purposes

Similar Documents

Publication Publication Date Title
UY34736A (en) ? INDOL AND INDAZOL COMPOUNDS THAT ACTIVATE AMPK ?.
ECSP17016797A (en) INDAZOLES SUBSTITUTED WITH BENZYL AS BUB1 INHIBITORS
CR20130565A (en) FUSIONATES DERIVED FROM USEFUL IMIDAZOL AS IDO INHIBITORS
EA201891910A1 (en) PAD4 HETEROARYLINARY INHIBITORS
CL2016001082A1 (en) Process for the synthesis of an indolamine 2,3-dioxygenase inhibitor
CL2015002932A1 (en) Protein kinase inhibitors
BR112016023851A2 (en) ? two-part coating composition and method for coating a surface?
EA201691594A1 (en) CYCLOPROPYLAMINES AS LSD1 INHIBITORS
EA202090632A1 (en) METHODS AND COMPOSITIONS FOR TREATING DISORDERS WITH THE USE OF FALLISTATIN POLYPEPTIDES
EA201592005A1 (en) BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
UY35798A (en) INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEIVER
PE20151594A1 (en) INDOLAMINE 2-3 DIOXYGENASE INHIBITORS
MX2017003637A (en) Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors.
EA201692435A1 (en) CONNECTION SALTS (S) -2- (1- (6-AMINO-5-CYANOPYRIMIDIN-4-ILAMINO) ETIH) -4-OXO-3-PHENYL-3,4-DIGYDROPYRROLO [1,2-F] [1, 2,4] TRIAZIN-5-CARBONITRILE
UY35464A (en) KRAS G12C COVALENT INHIBITORS.
MX2016012368A (en) Combinations of an fgfr inhibitor and an igf1r inhibitor.
UY35385A (en) ? METHODS AND COMPOSITIONS FOR WEED CONTROL ?.
LT3424920T (en) Co-crystals of (s)-n-methyl-8-(1-((2`-methyl-[4,5`-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
UY34342A (en) ? DERIVATIVES OF PIRROLOPIRIMIDINA AND PURINA ?.
EA201691032A1 (en) IZHOCHROMEN DERIVATIVES AS PHOSFOINOSYTID-3-KINAZ INHIBITORS
EA201692313A1 (en) Derivatives of indolysine as inhibitors of phosphosinositide-3-kinase
EA201891347A1 (en) Aza-benzimidazole inhibitors PAD4
EA201791530A1 (en) NEW N-ACYLARYL SULPHONAMIDE DERIVATIVES AS AN INHIBITORS AMINOACYL-tRNA SYNTHETASIS
CY1122403T1 (en) DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE
BR112017011642A2 (en) compound, pharmaceutically acceptable salt, and method for treating a disease or condition that benefits from an increase in nad +.